QL 2109
Alternative Names: QL-2109Latest Information Update: 24 Dec 2024
Price :
$50 *
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Dec 2024 Qilu Pharmaceutical plans phase-III trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in January 2025 (SC, infusion) (NCT06742138)
- 17 Apr 2024 Preclinical trials in Solid tumours in China (SC) before April 2024
- 17 Apr 2024 Qilu Pharmaceutical plans a phase I trial for Cancer (In volunteers) in China (SC, Injection) in April 2024 (NCT06371534)